About PILA PHARMA
Pila Pharma AB is a clinical stage biotech company developing a potent, selective TRPV1 antagonist, XEN-D0501, as treatment of type 2 diabetes and the rare painful disease erythromelalgia.
XEN-D0501 has been tested in 300 subjects in phase 1 and 2 and has a demonstrated good safety profile in healthy volunteers and in patients with overactive bladder disease, chronic cough or type 2 diabetes as well as efficacy in type 2 diabetics on improving glucose stimulated insulin secretion.
Recently, 13 week preclinical safety studies with XEN-D0501 completed without registration of side effects and the molecule can therefore progress to clinical trials of up to 3 months duration.
In July 2022, the company received US Orphan Drug Designation for XEN-D0501 as treatment as the rare and painful disease erythromelalgia.
The company is based in Malmö, Sweden and is listed on Nasdaq First North GM, Stockholm,
since July 2021.
The company is whole owner of private Danish subsidiary Pila Pharma Danmark ApS, Denmark.
The company welcomes partners and investors for the next development stages.
FÅ PRESSMEDDELANDEN / GET PRESS RELEASES
MEET US AT
Our CEO Dorte X. Gram will be participating in the Annual meeting of the European Association for the Study of Diabetes and will be available for meetings.
Please request meeting at info@pilapharma.com
News
(03 Oct-2023)
(29 Sep-2023)
On August 28, 2023 in Finans Stockholm, our CEO For Dorte X Gram gave some hints at how PILA PHARMA will proceed and be relevant with our TRPV1 antagonist treatment.
Please, find the link to the video (in English) here
(07 Sep-2023)
CORRECTION: Clarification and extended information on previous press release regarding convertible loans and their structure.
PILA PHARMA announces capital infusion via convertible loans
Read the press release (in English) here
(24 Aug-2023)
Interim Report Pila Pharma (1 April – 30 June 2023)
Read the Report (in English) here
(23 Aug-2023)
PILA PHARMA publishes interim report (1 April – 30 June 2023)
Read the press release (in English) here
(23 Aug-2023)
Pila Pharma ändrar språk för informationsgivning till engelska
Läs pressmeddelande (in Swedish) här
(22 Aug-2023)
CEO of Pila Pharma, Dorte X. Gram, interviews Matt Sondag about the thoughts and challenges of a living with erythromelalgia, a rare disease with periods of intense pain.
Please, find the link to the video (in English) here
(2 June-2023)
KOMMUNIKE FRÅN ÅRSSTÄMMA I PILA PHARMA AB 2023
Läs pressmeddelande (in Swedish) här
(1 June-2023)
CEO Dorte X. Gram presenting PILA PHARMA’s diabete drug project for the treatment of type 2 diabetes at the Diabetes Event hosted by Redeye.
Please, find the link to the video (in English) here
(26 May-2023)
CEO Dorte X. Gram presenting PILA PHARMA’s new orphan drug project for the treatment of rare disease Erythromelalgia at the Orphan Drugs day hosted by Redeye.
Please, find the link to the video (in English) here
Årsredovisning 2022 Pila Pharma
Läs rapporten PDF (in Swedish) här
(26 April-2023)
Delårsrapport 1 januari – 31 mars 2023
Läs rapporten PDF (in Swedish) här
(26 April-2023)
Happy to have been featured with the frontpage and a good article this week in the special section “Hälsa & Forskning” from Swedish newspaper Svenska Dagbladet!
It elaborates a little on our increased focus on our orphan drug designation and the perspectives and possibilities it gives.
Dorte X. Gram / Elna Lembrér Åström / Gustav Hanghøj Gram
Läs (in Swedish) här
(15 April-2023)
Presentation from the 15th annual Lifescience Capital Markets day in Stockholm hosted by Stockholm Corporate Finance and Financial Hearings. CEO, Dorte X. Gram gives a brief update on the company, status and thoughts/plans for the next foreseeable future.
Please, find the link to the video (in English) here
(10 March-2023)
Bokslutskommuniké 1 JANUARI – 31 DECEMBER 2022
Läs rapporten PDF (in Swedish) här